Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus

Endocrine journal

Kenichi Tanaka¹  Keiichi Torimoto¹  Yoshiya Tanaka¹  Manabu Narisawa¹  Kei Sugai¹  Maiko Hajime¹  Akira Kurozumi¹  Hiroko Mori¹  Satomi Sonoda¹  Megumi Miyazaki¹  Fumi Kuno¹  Tadashi Arao¹  Yosuke Okada¹  Shinichiro Mine² 

[1] First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu 807-8555, Japan;Sasaki Hospital, Kitakyushu 807-1114, Japan

关键词: Type 2 diabetes;    Alogliptin;    Vildagliptin;   

DOI  :  10.1507/endocrj.EJ16-0341

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

The aim of this 24-week, prospective randomized open-label study was to compare the effects of alogliptin and vildagliptin on glucose control, renal function, and lipid metabolism.In Study 1, DPP-4 inhibitor-naive type 2 diabetes (T2DM) were randomly assigned to alogliptin 25 mg/day or vildagliptin 50 mg twice daily.In Study 2, T2DM on treatment with 50 mg/day sitagliptin were switched to either 25 mg/day alogliptin or 50 mg twice daily vildagliptin.The primary endpoint was change in glycosylated hemoglobin (HbA1c) level at 24 weeks, while the secondary endpoints were changes in urinary albumin excretion and low-density lipoprotein cholesterol (LDL-C) levels at 24 weeks.In Study 1, HbA1c levels changed at 24-week by -0.5±0.7% in the alogliptin group (p=0.002, relative to baseline) and -0.7±0.9% in the vildagliptin group (p=0.001, relative to baseline), and the extent of these changes were comparable between the two groups (p=0.219).The decrease in log urinary albumin excretion was more significant in the vildagliptin group (p=0.008).In Study 2, HbA1c levels at 24-week changed by 0.2±0.7% in the switch-to-alogliptin group (p=0.007) and 0.0±0.6% in the switch-to-vildagliptin group (p=0.188), indicating a significant difference between the groups (p=0.003).In both studies, the changes in LDL-C levels were comparable between the two groups.The two drugs had comparable glucose-lowering effects in DPP-4 inhibitor-naive patients but the effect was more pronounced for vildagliptin in patients switched from sitagliptin.The results may point to subtle yet important differences between the two DPP-4 inhibitors.This trial was registered with UMIN (no. #000019022).

【 授权许可】

Unknown